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Abstract
Background: While some risk factors for breast cancer are well-known, the influence of other factors, particularly
virus infection, remains unclear. Human cytomegalovirus (HCMV) is widespread in the general population, and both
molecular and epidemiological evidence has indicated links between HCMV and breast cancer. The HCMV protein
cmvIL-10 is a potent suppressor of immune function that has also been shown to promote proliferation and migration of breast cancer cells. In this study, the impact of cmvIL-10 on tumor cell invasion through a simulated basement
membrane was investigated.
Results: MDA-MB-231 breast cancer cells exhibited invasion through a matrigel layer that was significantly enhanced
in the presence of either purified cmvIL-10 or supernatants from HCMV-infected cells containing secreted cmvIL-10.
Transcriptional profiling revealed that cmvIL-10 altered expression of several genes implicated in metastasis. Exposure
to cmvIL-10 resulted in higher MMP-3 mRNA levels, greater protein expression, and increased enzymatic activity. Treatment with cmvIL-10 also increased expression of both urokinase plasminogen receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1), which can stimulate MMP-3 activity and have previously been identified as poor prognostic
markers in breast cancer patients. Finally, MDA-MB-231 cells treated with cmvIL-10 showed significant downregulation
of metastasis suppressor 1 (MTSS1), a scaffolding protein that regulates cytoskeletal rearrangements and is frequently
lost in metastatic tumors.
Conclusions: HCMV, and in particular the secreted viral cytokine, cmvIL-10, can induce cellular changes that facilitate
cell migration and invasion. These findings indicate that HCMV may be associated with promoting the malignant
spread of breast cancer cells and suggest that antiviral treatment may be a useful complement to chemotherapy in
some patients.
Keywords: Breast cancer, Cytokine, Cytomegalovirus, cmvIL-10, Invasion
Background
Breast cancer is the second leading cause of cancer deaths
for women in the United States and a significant cause of
mortality worldwide. While there are many known risk
factors for breast cancer, infectious disease has emerged
as one likely contributor to carcinogenesis [1, 2]. Recent
studies have implicated a number of different viral infections in breast cancer, including bovine leukemia virus
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[3, 4], human mammary tumor virus [5], human papillomavirus [6], Epstein–Barr virus (EBV) [7–9], and human
cytomegalovirus (HCMV) [10, 11]. Although there is no
clear causal role for any of these viruses, a combination
of molecular and epidemiological evidence suggests an
association between HCMV and breast cancer.
HCMV is a β-herpesvirus that infects 70–90% of the
general population, causing acute, persistent, or lifelong latent infection [12]. HCMV infections are typically subclinical and serious disease occurs mainly in
immune-compromised individuals [12]. Overall, HCMV
serostatus has not been positively correlated with breast
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cancer; however, women with breast cancer were found
to have higher mean HCMV IgG levels in an Australian
case–control study [13], suggesting that they might have
experienced a recent infection. Analysis of a Norwegian
cohort by the same group also revealed that elevation of
HCMV IgG, but not EBV IgG levels, preceded the development of breast cancer in some women [14].
While serological evidence for HCMV in breast cancer
may be limited, a stronger case is made by studies that
have detected viral DNA and proteins by PCR and immunohistochemistry (IHC) in tumor biopsy specimens. In
Taiwan, analysis of 62 breast cancer patients found that
detection of both HHV-8 and HCMV in tumor samples
by PCR was associated with lower overall survival and a
decrease in relapse-free time [6]. Harkins et al. detected
HCMV immediate early (IE) proteins by IHC in breast
glandular epithelial cells in 31 of 32 specimens from
patients with ductal carcinoma in situ (DCIS) or infiltrating ductal carcinoma (IDC) [10]. Another study found
both HCMV IE and late proteins expressed in metastatic
tumor cells in 100% of breast cancer specimens analyzed
(73 total), and viral DNA was detected in 12/12 samples
tested [11]. Detection of virus in breast epithelial cells is
consistent with the notion that epithelial cells are a site of
HCMV persistence [15], and further supported by the fact
that transmission of infectious virus through breast milk
is well-documented [16–19].
Despite the evidence indicating the presence of viral
proteins and DNA in breast tumor tissue, HCMV is not
typically considered an oncogenic virus [20]. Virus infection can, however, promote many of the classic hallmarks
of cancer [21, 22], such as cell cycle dysregulation, inhibition of apoptosis, increased migration and invasion, and
immune evasion [20, 23]. HCMV has been linked not
only to breast cancer, but to an array of other malignancies, including glioblastoma [24–27], medulloblastoma
[28], colon cancer [29], and prostate cancer [30]. Individual HCMV gene products can have profound effects
on cell growth, such as immediate early proteins IE1 and
IE2, which are known to stimulate entry into S phase [31,
32]. IE1 expression was found to increase the growth
rate of glioblastoma cells in culture, suppress p53 and Rb
tumor suppressor activity, and stimulate PI3K/Akt signaling [33]. IE1 was detected in breast tumor tissue [10,
11] as well as in CD133+ glioma stem cells isolated from
glioblastoma multiforme (GBM) patients [34], suggesting that IE1 may promote tumorigenesis enhancing the
growth and self-renewal of tumor stem cells.
Another HCMV gene implicated in tumor development is US28, which encodes a functional chemokine
receptor that binds several human chemokines, including CCL2/MCP-1, CCL5/Rantes, and CX3CL1/Fractalkine [14, 35]. US28 also exhibits constitutive signaling
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activity, and cells expressing US28 are highly invasive [27]
and form tumors in nude mice [36, 37]. US28 was found
to induce vascular endothelial growth factor (VEGF),
cyclooxygenase-2 (COX2), and Stat3 activation through
upregulation of IL-6 [36–38]. Analysis of glioblastoma
tumor specimens revealed the presence of both US28 and
phosphorylated Stat3 [27, 38], demonstrating that US28
may play role in tumor development in vivo.
Whereas the US28 and IE1 gene products are
expressed in infected cells, the UL111A gene encodes
cmvIL-10, a viral cytokine that is secreted from infected
cells. Although cmvIL-10 has only 27% sequence identity
to human interleukin-10 (hIL-10) [39], the viral cytokine
binds to the cellular IL-10 receptor with greater affinity
than hIL-10 itself [40]. Extensive immunosuppressive
properties of cmvIL-10 have been documented, including
inhibition of inflammatory cytokine synthesis, downregulation of class I and II MHC, and inhibition of dendritic
cell maturation [41–48]. Engagement of the IL-10 receptor by cmvIL-10 leads to activation of Stat3 [49–53],
which is commonly constitutively activated in breast cancer cells [54], associated with poor prognosis in ovarian
cancer, and considered a key factor in metastasis formation [55]. CmvIL-10 was found to activate Stat3 and play
a pivotal role in the progression of malignant glioma by
enhancing the invasiveness and migration of glioma cancer stem cells [56]. Because cmvIL-10 is secreted from
the infected cell, it has the potential to act on any cell
type, infected or not, that expresses the IL-10 receptor.
We have previously shown that the breast cancer cell
lines MDA-MB-231 and MCF-7 express the IL-10R and
that exposure to cmvIL-10 results in enhanced cell proliferation and migration [57, 58]. In the present study, we
examined the impact of cmvIL-10 on MDA-MB-231 cell
invasion through a simulated basement membrane and
investigated the effect of cmvIL-10 on a panel of metastasis-related genes. We found that cmvIL-10 was a potent
enhancer of invasion and influenced expression of genes
strongly linked to the metastatic spread of breast cancer.

Methods
Cell, viruses, and reagents

MDA-MB-231 human breast adenocarcinoma cells
(American Type Culture Collection, Manassas, VA) were
cultured in L-15 Leibovitz’s Medium (Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum
(FBS) (Atlanta Biologicals, Flowery Branch, GA) at 37 °C
with atmospheric CO2. The human foreskin fibroblast
(HFF) cell line (ATCC) was cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% FBS at 37 °C in a
humidified chamber with 5% CO2. Human cytomegalovirus strain AD169 (ATCC) was used to infect confluent monolayers of HFFs at the indicated multiplicities of
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infection. Purified recombinant cmvIL-10, human IL-10,
and epidermal growth factor (EGF) were purchased from
R&D Systems (Minneapolis, MN). IL-10R neutralizing
antibody and S3I-201 Stat3 inhibitor were from Santa
Cruz Biotechnology (Santa Cruz, CA).
Migration and invasion assays

Transwell migration was monitored using 96-well BD
Fluoroblock plates with 8 µm filters (Corning, Inc., Corning, NY). Cells were harvested and suspended at density
of 2 × 106 cells/ml in migration media (L-15 + 1% FBS),
and a volume of 75 μl cell suspension was placed on top
of the filter inserts. Where indicated, IL-10R neutralizing
antibody was added at a concentration of 30 μg/ml. The
bottom wells were loaded with the indicated concentrations of EGF in the presence of conditioned medium from
mock or HCMV-infected fibroblasts (96 h post infection)
in a total volume of 235 μl. After 5 h at 37 °C, cells that
traversed the filter and entered the lower chamber were
quantified by the addition of Cell Titer Glo (Promega,
Madison, WI) using a Turner Veritas luminometer. For
invasion, 96-well matrigel-coated BD Fluoroblock transwell invasion plates (Corning) were used. Invasion plates
were re-hydrated with warm media at 37 °C for 3 h and
then 75 μl cell suspension loaded onto the hydrated filters
as described above. Where indicated, 10 μM Stat3 inhibitor was included with cells in the top chamber; cmvIL-10,
hIL-10 or conditioned medium was present in both chambers. The bottom plates received the indicated EGF concentrations, and then transwell system was incubated for
22 h at 37 °C with atmospheric CO2. At harvest, cells that
had degraded the matrigel and entered the lower chamber
were quantified by the addition of Cell Titer Glo as above.
Quantitative PCR arrays

RNA was harvested from 10 × 106 MDA-MB-231 cells
that were mock treated or treated with 100 ng/ml cmvIL10 or hIL-10 for 5 h using the RNeasy Midi Kit and
RNAse-Free DNase set (Qiagen, Valencia, CA). From the
isolated RNA, cDNA was prepared using the RT2 First
Strand Kit (SA Biosciences, Frederick, MD) and subsequently loaded into a 96-well breast cancer metastasis
profiler PCR array (PAHS-028ZD) with system RT2 SYBR
Green Mastermix (SA Biosciences). The plates were run
using the CFX96 Real-Time system cycler (BioRad, Hercules, CA) with the following amplification program:
95 °C for 10 min, 95 °C for 15 min with a slow ramp rate
for 1.0 c/s and 60 °C for 1 min. The data from three biological replicates for each treatment was analyzed by the
ΔΔCT method according to manufacturer’s instructions
using the RT2 profiler PCR array data analysis program
located on the SABiosciences web portal and is reported
as fold change relative to control.
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Enzyme‑linked immunosorbent assay (ELISA)

DuoSet ELISA kits (R&D Systems) were used to quantify
uPAR, PAI-1, and MMP-3. For uPAR and PAI-1 measurement, MDA cells were seeded in triplicate in 96-well
plate at 5.0 × 104 cell/ml density with complete L-15
media and treated with 10 ng/ml of either cmvIL-10 or
hIL-10 for the indicated times and supernatants were
collected daily. The ELISA was carried out on supernatants according to manufacturer’s instructions using and
following the addition of substrate and stop solution,
absorbance of the plate was measured at 450 nm using
a Dynex Opsys MR microplate reader. Sample concentrations were interpolated from a standard curve using
linear regression analysis. For cell-associated MMP3, MDA cells were seeded in 96-well plates and treated
with cmvIL-10 as above. Cells were treated with cell
lysis buffer (150 mM NaCl, 20 mM HEPES, 0.5% TritonX-100, 1.0 mM NaOV4, 1.0 mM EDTA, 0.1% NaN3) supplemented with 1× protease inhibitors (Calbiochem,
EMD Chemicals, San Diego CA) and were collected daily
for the indicated time points. The lysates were evaluated
for MMP-3 according to the manufacturer’s instructions
(R&D Systems).
Western blotting and zymography

Confluent T-75 flasks of MDA-MB-231 cells were treated
with 10 ng/ml cmvIL-10 (R&D systems) for the indicated
times, then scraped and harvested into cell lysis buffer
(150 mM NaCl, 20 mM HEPES, 0.5% Triton-X-100,
1.0 mM NaOV4, 1.0 mM EDTA, 0.1% NaN3) containing 1× protease inhibitors (Calbiochem). Cell lysates
were clarified via centrifugation, heated at 70 °C for
10 min in reducing buffer, and the proteins separated
on a 4–12% Tris-Base SDS-PAGE gel (Life Technologies, Grand Island, NY). After transfer to nitrocellulose,
the membrane was incubated in blocking solution (5%
milk + TBS) for 1 h at room and then probed with primary antibody: 1:1000 dilution for MMP-3 or MTSS-1
antibodies (Santa Cruz), or MAPK antiserum (Cell Signaling Tech, Danvers, MA), in blocking solution overnight, oscillating on a platform rocker at 4.0 °C. After
three washes, the membranes were incubated with a
1:2000 dilution of appropriate AP-conjugated secondary antibody on a platform rocker at room temperature
for 1 h. Protein bands were detected using western blue
stabilized AP substrate (Promega, Madison, WI). For
zymography, cell lysates were denatured in SDS buffer
under non-reducing conditions without heat, and run on
a 4–16% Zymogram gel using Tris–Glycine SDS running
buffer according to manufacturer’s instructions. After
electrophoresis, the enzyme was renatured by incubating the gel in Zymogram Renaturing Buffer containing
a non-ionic detergent, then equilibrated in Zymogram
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Developing Buffer (to add divalent metal cations required
for enzymatic activity), and then stained and destained
to reveal digested (clear) areas corresponding to active
enzyme.
Immunofluorescence microscopy

MDA-MB-231 cells were seeded onto FBS-coated glass
coverslips at a density of 2.0 × 105 cells/well and cultured
for 48 h at 37 °C. Cells were treated with 100 ng/ml of
purified recombinant cmvIL-10 for 96 h, then fixed with
2% paraformaldehyde in DPBS for 20 min, washed, permeabilized with 0.2% Triton-X-100 in PBS for 15 min.
The cells were washed and blocked with 10% FBS for
1 h at 37 °C, then incubated with anti-MTSS-1 antibody
at a 1:100 dilution for 1 h at 37 °C followed by the addition of goat anti-mouse TRITC secondary antibody at a
1:150 dilution for 30 min (Life Technologies) and Alexa
Fluor 488 phalloidin (Molecular Probes, Eugene, OR).
Coverslips were washed and excess fluid was removed
before inverting the coverslip onto a glass slide containing 20 μl of DAPI-containing Prolong Gold mounting
medium (Life Technologies, Grand Island, NY). Images
were taken on a Zeiss AX10 Imager.A1 microscope (Carl
Zeiss Inc., Oberkochen, Germany) using AxioVision 4.7.2
imaging software.
Statistical analysis

Statistical analyses was performed using the paired, twotailed Student’s t test.

Results and discussion
The tumor microenvironment is a complex milieu that
includes not only malignant cells, but immune cells,
fibroblasts, signaling molecules, the extracellular matrix
(ECM), and blood vessels. We have previously found that
cmvIL-10 enhances migration of MDA-MB-231 breast
cancer cells in vitro toward epidermal growth factor (EGF)
[57]. In order to more faithfully replicate conditions under
which cmvIL-10 might be found in the tumor microenvironment, we examined the ability of cmvIL-10 secreted
from virus-infected cells to stimulate movement of MDA
cells. Monolayer cultures of human foreskin fibroblasts
were mock-infected or infected with HCMV strain AD169
at a range of multiplicities of infection (MOI). After 96 h,
supernatants were harvested and placed in the lower
chamber of a transwell migration plate in the presence or
absence of EGF. MDA cells were placed in the upper chamber, separated from the EGF and conditioned medium by a
porous filter. After five hours, cells that traversed the filter
were quantified. MDA cells did not exhibit any significant
movement toward conditioned medium from mock or
infected cells, which is consistent with our previous finding that cmvIL-10 is not a chemoattractant for tumor cells
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[57]. However, when conditioned medium from mock
infected cells was supplemented with EGF, cell migration
was observed (Fig. 1a). When EGF was added to conditioned medium from HCMV-infected cells, the amount
of cell migration increased, suggesting that substances
released from virus-infected cells amplified chemotaxis
to EGF. Moreover, the enhanced MDA cell movement
was greater when EGF was provided in supernatants from
higher MOI infections, and thus greater concentrations of
cmvIL-10, indicating a dose-dependent effect. To confirm
that cmvIL-10 was the virally produced substance mediating this increase in cell movement, MDA cells were preincubated for 30 min with a neutralizing antibody (NAb)
directed at the cellular IL-10R. The NAb was also included
in the top chamber with MDA cells during the 5 h incubation, and resulting migration was reduced to levels
seen when only EGF was present in medium from mock
infected cells. These results demonstrate that cmvIL-10
secreted from virally infected cells has the ability to interact with the cellular IL-10R on tumor cells to enhance
directed movement.
To further recapitulate the tumor microenvironment,
we examined whether cmvIL-10 could also promote
invasion through matrigel, a gelatinous protein mixture
derived from mouse sarcoma cells widely used to simulate the ECM in vitro [59]. MDA cells were place atop a
matrigel-coated transwell system with EGF placed in
the lower chambers. Purified recombinant cmvIL-10 or
hIL-10 was added to both chambers. After incubation
for 22 h, invasion was assessed by counting cells in the
lower chamber, which should contain only the cells that
were able to degrade the matrigel coating to access the
porous filter. As shown in Fig. 1b, cmvIL-10 was found
to be a strong enhancer of cell invasion. Surprisingly,
cmvIL-10 was able to increase invasion of MDA breast
cancer cells to a significantly greater extent than hIL-10,
suggesting that the viral cytokine may trigger signaling
events that are distinct from the cellular cytokine. Since
activation of the transcription factor Stat3 by cmvIL-10 is
well-documented [39, 49–51, 53, 60, 61], we next examined the need for Stat3 in cmvIL-10-enhanced invasion.
Treatment with a Stat3 inhibitor reduced the cmvIL10-induced increase in invasion through matrigel toward
EGF seen when either recombinant purified protein or
cytokine produced during virus infection were present
(Fig. 1c). Taken together, these results demonstrate the
novel finding that not only does cmvIL-10 produced during virus infection stimulate enhanced migration and
invasion of breast cancer cells, but it does so more effectively than hIL-10.
Given the impact of cmvIL-10 on MDA cell invasion,
we wanted to investigate whether the viral cytokine
brought about changes in the expression of genes
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associated with tumor metastasis. Transcriptional profiling was performed using a tumor metastasis qPCR array
designed to analyze 84 genes known to be involved in
breast cancer metastasis. MDA cells were mock-treated
or incubated with either cmvIL-10 or hIL-10 for 5 h, then
RNA was extracted, cDNA synthesized, and qPCR performed. Additional file 1: Table S1 contains a complete
list of genes analyzed with fold changes for cmvIL-10 or
hIL-10 treated cells compared to mock treated control
cells indicated. Select genes encoding proteins associated
with either the ECM (Fig. 2a) or cell adhesion (Fig. 2b)
are shown graphically. Overall, plasminogen activator
inhibitor (PAI-1) was the most highly upregulated gene
for both cytokines, with expression increased by 2.68fold by cmvIL-10 and 3.12-fold by hIL-10. Interestingly,
increased expression of urokinase plasminogen receptor
(uPAR) was also common to both cmvIL-10 and hIL-10
(1.59- and 1.87-fold increases, respectively). Matrix metalloproteinase-3 (MMP3) was specifically upregulated
by cmvIL-10 only (2.75-fold increase), while collagen
type 4 (COL4A) expression was increased by hIL-10 only
(1.51-fold increase). Changes in cell adhesion genes were
more modest, with only one gene, metastasis suppressor
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Fig. 1 MDA-MB-231 cells exhibit increased migration and matrigel
invasion in the presence of cmvIL-10. a Transwell migration toward
EGF after 5 h in the presence of conditioned medium from mock or
HCMV-infected fibroblasts at the indicated MOIs. IL-10R neutralizing
antibody (NAb) was included at 30 μg/ml. b Matrigel invasion toward
EGF in the presence of 100 ng/ml purified recombinant cmvIL-10 or
hIL-10 after 22 h. c Matrigel invasion toward EGF in the presence or
absence of 100 ng/ml purified recombinant cmvIL-10 or conditioned
medium from mock or infected fibroblasts (MOI = 1). Where indicated, 10 μM Stat3 inhibitor was included. Error bars SEM. *p < 0.05,
**p < 0.001. These results are representative of three independent
experiments
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Fig. 2 CmvIL-10 induces changes in metastasis-related gene expression in MDA-MB-231 cells. RNA was extracted from cells treated
with 100 ng/ml cmvIL-10 or hIL-10 for 5 h, then RNA was purified
and expression of 84 genes was analyzed using the Human Tumor
Metastasis RT2 Profiler PCR Array. a Select genes encoding extracellular matrix proteins or b cell adhesion proteins is shown. Fold changes
represent comparison to untreated MDA-MB-231 and are the average
of three biological replicates. Error bars SEM. *p < 0.05. A complete list
of genes analyzed is found in Additional file 1: Table S1
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1 (MTSS1) exhibiting a statistically significant change
of more than twofold, and this was observed for cmvIL10 treatment only (0.305-fold change, or −3.28). Slight
decreases in integrin alpha 7 (ITGA7, 0.561- or −1.78fold change), melanoma cell adhesion factor (MCAM,
0.768- or −1.32-fold change), and cadherin 6 (CDH6,
0.811- or −1.23-fold change) were also found with
cmvIL-10 treatment. Both cmvIL-10 and hIL-10 induced
a slight decrease in expression of vascular endothelial
growth factor (VEGFA, 0.554- or −1.80-fold for cmvIL10; 0.5987- or 1.67-fold change for hIL-10). Chemokine
receptor CXCR2 expression was also strongly decreased
by cmvIL-10 and hIL-10, but those changes were not statistically significant. Overall, these transcriptional profiling results indicate that cmvIL-10, as well as human
IL-10, can affect expression of genes that are likely to
promote metastatic spread of tumor cells.
The most significantly upregulated gene by both
cmvIL-10 and hIL-10 was PAI-1, or plasminogen activator inhibitor 1. PAI-1 is a 43 kDa glycoprotein that
inhibits the function of urokinase plasminogen activator
(uPA), a serine protease that catalyzes the conversion of
inactive plasminogen to plasmin and has been implicated
in many aspects of tumor progression [62]. The activity
of uPA system is regulated by the receptor uPAR and two
endogenous inhibitors, PAI-1 and PAI-2 [62]. PAI-1 is
constitutively secreted by many cell types and high levels have been found to inhibit cell adhesion and promote
migration [63, 64]. In order to confirm that changes in
gene expression identified by the qPCR array correlated
with protein expression, MDA cells were treated with
cmvIL-10 or hIL-10 and PAI-1 levels measured by ELISA.
As expected, PAI-1 was produced by untreated cells,
however, the amount of protein secreted was significantly
increased by cmvIL-10 after 12 h of exposure (Fig. 3a).
After 24 h, both cmvIL-10 and hIL-10 stimulated a significant increase in PAI-1 production, and this was maintained over 72 h. In addition, we examined uPAR protein
levels and found that they were also elevated upon exposure to cmvIL-10 or hIL-10 (Fig. 3b). These results demonstrate that expression of two elements of the uPA
serine protease system, its receptor uPAR and its serpin
inhibitor PAI-1, are significantly increased by cmvIL-10
and hIL-10 in human breast cancer cells.
Next we examined MMP-3, a member of the matrix
metalloproteinase family that has the ability degrade
many components of the extracellular matrix, such
as collagen III-V, and IX-XI, as well as laminins, elastins, fibronectin, vitronectins and proteoglycans [65].
Mouse epithelial mammary cells cultured with MMP-3
had decreased expression of cytokeratin markers and
increased expression of vimentin, a clear sign of the
epithelial-to-mesenchymal transition (EMT), in which
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Fig. 3 PAI-1 and uPAR levels are elevated upon exposure to cmvIL-10
or hIL-10. a MDA-MB-231 cells were cultivated in the presence of
10 ng/ml purified recombinant cmvIL-10 or hIL-10. At the indicated
time points, culture supernatants were collected and levels of PAI-1
measured by ELISA. b MDA cells were cultured as above and levels
of uPAR in the supernatant were determined by ELISA. Error bars
represent standard error among three replicates for each data point.
*p < 0.05. These results are representative of three independent
experiments

epithelial cells morph into a mesenchymal-type cell to
eliminate their connection to the basement membrane
and initiate migration towards subsequent intravasation into blood vessels [66]. MMP-3 can also activate
other MMPs, and high levels of MMP-3 correlate with
poor prognosis in breast cancer patients [67]. MDA cells
were treated with cmvIL-10 and then total MMP-3 levels
were measured by ELISA. We were unable to detect any
MMP-3 in cell supernatants, but cell-associated MMP-3
was detected by analysis of cell lysates. Relatively low levels of MMP-3 were produced by untreated MDA cells,
but this amount increased significantly after 48 h of treatment with cmvIL-10 (Fig. 4a). Since MMPs are generally
secreted as inactive pro-enzymes that require cleavage
to become activated, we further examined MMP-3 by
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western blotting and zymography. Consistent with the
ELISA results, an increase in total MMP-3 protein was
observed over time with exposure to cmvIL-10 (Fig. 4b).
The amount of active MMP-3 enzyme was also increased
by cmvIL-10 treatment, as evidence by increased digestion of casein in the zymogen gel. Taken together, these
results indicate that cmvIL-10 promotes increased
expression and activation of MMP-3 by breast cancer
cells, which is likely to contribute to increased degradation of the ECM and greater risk of metastasis.
MTSS1 was notable as the gene most strongly downregulated by cmvIL-10 treatment. Also known as
missing-in-metastasis (MIM), MTSS1 was originally
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Fig. 4 MMP-3 expression and activity are increased by cmvIL-10.
a MDA-MB-231 cells were cultured in the presence or absence of
10 ng/ml cmvIL-10 for the indicated times and then cell lysates were
analyzed by ELISA. Error bars SEM, *p < 0.05. b MDA cells cultured
with 100 ng/ml cmvIL-10 for the indicated times were harvested and
lysates examined by western blotting with anti-MMP3 or anti-MAPK
as a protein loading control. Lysates from cells receiving the same
treatment were analyzed under non-reducing conditions on a 4–16%
Zymogram gel (lower panel). Arrow indicates active MMP-3. These
results are representative of three independent experiments
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identified as a tumor suppressor gene whose expression
was lost in metastatic bladder and prostate cancers [68].
The tumor suppressor works as a scaffold to inhibit the
dissociation of cell junctions and to increase adherens
junction formation, so when MTSS1 is lost, recruitment
of F-actin to the cytoskeleton is reduced, enabling tumor
cells to detach from the basement membrane and from
neighboring cells. MTSS1 has been found to be inversely
correlated to the aggressive invasive potential in several breast cell lines and with overall survival in breast
cancer patients [69]. To confirm that the reduced gene
expression observed on the PCR array correlated with a
decrease in MTSS1 protein levels, immunoblotting was
performed on lysates from MDA-MB-231 cells treated
with 10 ng/ml cmvIL-10. The expected 82 kD band was
detected for MTSS1 in untreated cells and was still visible
after 24 h of incubation with cmvIL-10 (Fig. 5a). However, as time progressed, the cmvIL-10-treated samples
showed a significant decrease in MTSS1 expression. In
contrast, the β-actin bands that serve as a loading control
remained constant. We further examined MTSS1 expression via immunofluorescence microscopy and found the
protein to be widely distributed throughout the cytoplasm in untreated MDA cells (Fig. 5b), which is consistent with its role in regulating cytoskeletal rearrangement.
After exposure to cmvIL-10, dramatic reduction in the
amount of MTSS1 protein was observed. This reduction
in MTSS1 corresponded to a noticeable change in cellular architecture, as cmvIL-10-treated cells appeared to
be thinner and have fewer substrate attachment points.
These results demonstrate that treatment with cmvIL-10
reduced the expression of MTSS1 in MDA cells, which
could contribute to the increased migration and invasion
observed in the presence of cmvIL-10.

Conclusions
The results that we present here characterize a new role
for cmvIL-10 beyond its well-known function as an
immune modulator during HCMV infection [42]. The
viral cytokine conferred MDA-MB-231 cells with heightened migration and invasion abilities and is likely to promote the development of breast cancer metastasis. While
our studies have been conducted in vitro using cell lines,
we propose an in vivo scenario in which latently infected
monocyte/macrophages infiltrate the developing tumor
and release cmvIL-10 (Fig. 6). Our observations that
cmvIL-10 reduces expression of MTSS1, while increasing
expression of uPAR, PAI-1, and MMP-3 suggest that the
secreted viral cytokine can act directly on breast epithelial cells expressing IL-10R to promote reduced cell–cell
adhesion and increased movement, ultimately leading to
invasion into the surrounding stromal tissue and entry
into bloodstream.
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Fig. 5 MTSS1 expression is significantly decreased upon exposure to cmvIL-10. a MDA-MB-231 cells were cultured with 100 ng/ml cmvIL-10 for the
indicated times and lysates examined by western blotting with anti-MTSS1 or anti-β-actin as a protein loading control. b MDA cells were seeded
onto glass coverslips in the presence of absence of 100 ng/ml cmvIL-10 for 96 h, then fixed, permeabilized, and stained as indicated. Scale bar
10 μm. These results are representative of three independent experiments

The evidence linking HCMV to breast cancer continues to grow, yet there is still considerable controversy in
field. While some groups have found traces of viral DNA
or proteins in tumor samples [6, 10, 11], other labs have
not been able to detect evidence of HCMV [70, 71]. This
may be due to differences in detection technique, sample preparation, and even tumor type. El-Shinawi et al.
have found evidence for HCMV in inflammatory breast
cancer (IBC), a highly metastatic and aggressive form
of breast cancer that is often associated with pregnancy
and occurs in at higher frequency in women of Northern
African and Egyptian descent [72]. They reported detection of more HCMV DNA in IBC tissues compared to
IDC, and higher HCMV IgG titers in IBC patients compared to IDC patients [72]. In a follow-up study, they
assessed viral genotypes and found a correlation between
mixed phenotypes and disease progression, notably lymphovascular invasion and formation of lymphatic emboli

in IBC patients, but not in women with other forms of
breast cancer [73]. The findings suggest that HCMV
may be more closely associated with specific subtypes of
breast cancer.
HCMV can infect a wide range of cell types that may
be present within the tumor microenvironment, such
as monocyte/macrophages, fibroblasts, epithelial and
endothelial cells. While several studies have found evidence for direct infection of tumor cells via IHC staining [10, 11], detection of viral DNA by PCR from fixed
tissue samples precludes direct identification of the cell
type harboring the virus. It may be that the cell type
infected varies from case to case, just like the combination of specific mutations that lead to tumor initiation in
a given individual. We favor the notion that immune cells
harboring latent HCMV infiltrate the tumor, because
monocytes are a well-documented reservoir for HCMV
[74–76] and this scenario could lead to significant
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Fig. 6 Model depicting possible role of cmvIL-10 in promoting tumor metastasis. A monocyte that is latently infected with HCMV infiltrates a
localized tumor, releasing cmvIL-10 that acts on tumor cells expressing the IL-10 receptor. This leads to changes in levels of MTSS1, uPAR and PAI-1,
which reduce cell adhesion. Increased levels of uPAR and PAI-1 are strongly associated with increased migration and can also help activate MMP-3.
Active MMP-3 degrades proteins in the extracellular matrix, facilitating access for tumor cells to invade surrounding stromal tissue and enter the
bloodstream

variability from tumor to tumor depending on the number of infected infiltrating cells and whether they reactivate virus that goes on to infect other cells in the tumor
microenvironment. Transcriptional analysis of HCMVinfected monocytes revealed a unique M1/M2 polarization signature that included induction of both M1 type
inflammatory cytokines like IL-1, IL-6, and TNFα, as
well as upregulation of M2 type cytokines like IL-10 and
IL-18 [77]. The presence of these conflicting signals in the
tumor environment has been associated with neoplastic
progression, suggesting that HCMV could tip the balance
in favor of this process [78].
Analysis of the secretome, or proteins produced by
HCMV-infected cells, has revealed high levels of both
MMP-3 and PAI-1 [79], which is consistent with our

observations that cmvIL-10 induces higher expression
of both of these proteins. The secretome was found to
promote angiogenesis and wound healing, and contained many growth factors, cytokines, chemokines, and
enzymes associated with metastasis, including MMP-1,
MMP-2, MMP-9, and MMP-10 [79]. Somiari and colleagues were able to detect elevated levels and activity
of MMP-2 and MMP-9 in plasma from breast cancer
patients, as well as in women determined to be high risk
based on Gail Model predictions [80]. This suggests that
it may be possible to develop a plasma protein profile
with a characteristic signature that identifies individuals
likely to develop breast cancer.
Although cmvIL-10 has not yet been quantified in
patient serum, measurement of cmvIL-10 and hIL-10 may
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also have prognostic value in breast cancer. Elevated levels of hIL-10 (27-2134 pg/ml) have already been detected
in the serum of some cancer patients and correlate with
poor prognosis [81–86], suggesting that hIL-10 may
contribute to immune suppression and tumor progression. In vitro, hIL-10 has been found to promote resistance to apoptosis in human breast and lung cancer cell
lines [87, 88]. Importantly, recent evidence suggests that
cmvIL-10 induces increased expression of hIL-10, potentially amplifying the immune suppressive environment
and enabling the invasive spread of tumor cells [60]. Our
results show that cmvIL-10 increased the migration and
invasive ability of MDA-MB-231 breast cancer cells and
affected expression of several metastasis-related genes.
Taken together, these findings suggest a new mechanism
for HCMV oncomodulation, as secretion of cmvIL-10 is
expected to manipulate the tumor microenvironment,
enhancing the potential of a developing breast tumor to
invade surrounding tissue, and ultimately establish metastatic tumors. Ultimately, it may be that a signature profile
of factors like cmvIL-10, hIL-10, MMPs, and PAI-1 could
have predictive or prognostic value for breast cancer. If
HCMV is truly involved in promoting tumor progression, chemotherapy treatment regimens that include anticmvIL-10 specific antibodies or even anti-viral drugs may
help improve the overall survival of cancer patients.

Additional file
Additional file 1. Transcriptional profiling of MDA-MB-231 cells exposed
to cmvIL-10 or hIL-10.
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